



18 April 2019

AIM: RENE

ReNeuron Group plc
("ReNeuron" or the "Company")

Share Purchases by Directors

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 18 April 2019 that, on the same day, the following purchases of the Company's ordinary shares of 1p each ("Ordinary Shares") were made by a director of the Company:

Name	Title	Number of Ordinary Shares purchased	Total beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
Professor Sir Chris Evans OBE	Non-executive Director	10,000	254,605	0.802

ENDS

ENQUIRIES:

ReNeuron

Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer

+44 (0)20 3819 8400

Buchanan

Mark Court, Sophie Wills, Tilly Abraham

+44 (0) 20 7466 5000

Stifel Nicolaus Europe Limited

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)

+44 (0) 20 7710 7600

Nplus1 Singer Advisory LLP

Aubrey Powell, Mark Taylor (Joint Broker)

+44 (0) 20 7496 3000

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further detail:

Notification and public disclosure of transactions by persons discharging managerial

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Professor Sir Chris Evans OBE	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	ReNeuron Group plc	
b)	LEI	2138003TU12CQ5TZO137	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares 1p RENE – GB00BF5G6K95	
b)	Nature of the transaction	Purchase of ordinary shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		2.287	10,000
d)	Aggregated information	N/A	
e)	Date of the transaction	18 April 2019	
f)	Place of the transaction	London Stock Exchange AIM Market	